PTGS2 and neoplasm: Celecoxib, a COX-2 inhibitor, significantly reduced tumor burden by 90% and notably delay tumor growth induced by the BRAFi inhibitor PLX7420.471 Copper chelation emerges as a potential treatment strategy for a specific subset of tumors characterized by activating BRAFV600E mutations.